$$
1 0 8 2 5 5 7
$$

# 510(k) Summary

# Applicant Contact Information:

Applicant: Address:

Instrumentation Laboratory Co. 113 Hartwell Avenue Lexington, MA 02421

DEC 1 9 2008

Contact Person: Carol Marble, Regulatory Affairs Director   
Alternate Contact: Gabriella Erdosy, Regulatory Affairs Associate   
Phone Number: 781-861-4467   
Fax Number: 781-861-4207   
Preparation Date: November 7, 2008

# Device Trade Names (Products Sold Separately):

HemosIL Routine Control Level 1

HemosIL Routine Control Level 2

HemosIL Routine Control Level 3

# Device Regulatory Information:

Common Name: Plasma, Coagulation Control   
Classification: Class ⅡI   
Product Code: GGN   
Regulation Number: 21 CFR 864.5425

# Identification of Predicate Devices:

K021023 HemosIL Normal ControlK021022 HemosIL Low Abnormal ControlK021024 HemosIL High Abnormal Control

# Device Descriptions:

The HemosIL Routine Control Level 1 is a lyophilized product prepared using human citrated plasma from healthy donors. It contains buffer, stabilizers and preservatives. The HemosIL Routine Control Level 2 is a lyophilized product prepared using human citrated plasma from healthy donors (not heparinized plasma or plasma samples under oral anticoagulant therapy) and modified, by means of a dedicated process, to stimulate an abnormal coagulation sample. It contains buffer and stabilizers. No preservatives are included. The HemosIL Routine Control Level 3 is a lyophilized product prepared using human citrated plasma from healthy donors (not heparinized plasma or plasma samples under oral anticoagulant therapy) and modified, by means of a dedicated process, to stimulate an abnormal coagulation sample. It contains buffer and stabilizers. No preservatives are included.

# 510(k) Summary (Cont.)

# Device Indications for Uses:

HemosIL Routine Control Level 1 is for the quality control of coagulation assays in the normal range. The product is intended in the assessment of precision and accuracy for PT, APTT and Fibrinogen tests performed on coagulation systems. HemosIL Routine Control Level 2 is for the quality control of coagulation assays in the low abnormal range. The product is intended in the assessment of precision and accuracy for PT and APTT tests performed on coagulation systems.   
• HemosIL Routine Control Level 3 is for the quality control of coagulation assays in the high abnormal range. The product is intended in the assessment of precision and accuracy for PT and APTT tests performed on coagulation systems.

# Statement of Technological Characteristics of the Device Compared to Predicate Devices:

HemosIL Routine Control Levels 1, 2 and 3 are substantially equivalent to the predicate devices in performance, intended use and safety and effectiveness for the claimed analytes.

Substantial Equivalence Comparison Table:   

<table><tr><td rowspan=1 colspan=1>Characteristic</td><td rowspan=1 colspan=1>New Device:HemosIL Routine Control Level 1</td><td rowspan=1 colspan=1>Predicate Device:HemosIL Normal Control(K021023)</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>For the quality control ofcoagulation assays in the normalrange.</td><td rowspan=1 colspan=1>Same, except additional analytes areclaimed for the indications for use.</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Human Plasma</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Form</td><td rowspan=1 colspan=1>Lyophilized</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Characteristic</td><td rowspan=1 colspan=1>New Device:HemosIL Routine Control Level 2</td><td rowspan=1 colspan=1>Predicate Device:HemosIL Low Abnormal Control(K021022)</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>For the quality control ofcoagulation assays in the lowabnormal range.</td><td rowspan=1 colspan=1>Same, except additional analytes areclaimed for the indications for use.</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Human Plasma</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Form</td><td rowspan=1 colspan=1>Lyophilized</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Characteristic</td><td rowspan=1 colspan=1>New Device:HemosIL Routine Control Level 3</td><td rowspan=1 colspan=1>Predicate Device:HemosIL High Abnormal Control(K021024)</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>For the quality control ofcoagulation assays in the highabnormal range.</td><td rowspan=1 colspan=1>Same, except additional analytes areclaimed for the indications for use.</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Human Plasma</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Form</td><td rowspan=1 colspan=1>Lyophilized</td><td rowspan=1 colspan=1>Same</td></tr></table>

# 510(k) Summary (Cont.)

# Summary Performance Data:

# Precision

Within run precision was assessed over multiple runs using the three levels of HemosIL Routine Control with specific lots of reagents on representative coagulation systems:

<table><tr><td rowspan=1 colspan=5>HemosIL Routine Control Level 1</td></tr><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>Reagent</td><td rowspan=1 colspan=1>Instrument</td><td rowspan=1 colspan=1>Mean(n=80)</td><td rowspan=1 colspan=1>Within-Run%CV</td></tr><tr><td rowspan=3 colspan=1>ProthrombinTime (PT)(Seconds)</td><td rowspan=1 colspan=1>HemosILPT-FibrinogenRecombinant(K981479)</td><td rowspan=1 colspan=1>ACL 9000</td><td rowspan=1 colspan=1>9.9</td><td rowspan=1 colspan=1>2.27</td></tr><tr><td rowspan=1 colspan=1>HemosILPT-Fibrinogen(K862301)</td><td rowspan=1 colspan=1>ACL Advance</td><td rowspan=1 colspan=1>11.5</td><td rowspan=1 colspan=1>1.48</td></tr><tr><td rowspan=1 colspan=1>HemosILPT-FibrinogenHS Plus(K060931)</td><td rowspan=1 colspan=1>ACL 300</td><td rowspan=1 colspan=1>13.4</td><td rowspan=1 colspan=1>1.46</td></tr><tr><td rowspan=3 colspan=1>Fibrinogen(mg/dL)</td><td rowspan=1 colspan=1>HemosILPT-FibrinogenRecombinant(K981479)</td><td rowspan=1 colspan=1>ACL 6000</td><td rowspan=1 colspan=1>270.9</td><td rowspan=1 colspan=1>3.91</td></tr><tr><td rowspan=1 colspan=1>HemosILPT-Fibrinogen(K862301)</td><td rowspan=1 colspan=1>ACL Advance</td><td rowspan=1 colspan=1>319.0</td><td rowspan=1 colspan=1>3.13</td></tr><tr><td rowspan=1 colspan=1>HemosILPT-FibrinogenHS Plus(K060931)</td><td rowspan=1 colspan=1>ACL 300</td><td rowspan=1 colspan=1>283.4</td><td rowspan=1 colspan=1>4.41</td></tr><tr><td rowspan=3 colspan=1>Activated PartialThromboplastin(APTT)(Seconds)</td><td rowspan=1 colspan=1>HemosILAPTT-SP(K973306)</td><td rowspan=1 colspan=1>ACL 9000</td><td rowspan=1 colspan=1>28.7</td><td rowspan=1 colspan=1>0.98</td></tr><tr><td rowspan=1 colspan=1>HemosILSynthAFax(K955638)</td><td rowspan=1 colspan=1>ACL 6000</td><td rowspan=1 colspan=1>20.5</td><td rowspan=1 colspan=1>0.91</td></tr><tr><td rowspan=1 colspan=1>HemosILSynthASil(K060688)</td><td rowspan=1 colspan=1>ACL Advance</td><td rowspan=1 colspan=1>30.1</td><td rowspan=1 colspan=1>1.15</td></tr></table>

# 510(k) Summary (Cont.)

# Summary Performance Data (Cont.):

# Precision

<table><tr><td rowspan=1 colspan=5>HemosIL Routine Control Level 2</td></tr><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>Reagent</td><td rowspan=1 colspan=1>Instrument</td><td rowspan=1 colspan=1>Mean(n=80)</td><td rowspan=1 colspan=1>Within-Run%CV</td></tr><tr><td rowspan=3 colspan=1>ProthrombinTime (PT)(Seconds)</td><td rowspan=1 colspan=1>HemosILPT-FibrinogenRecombinant(K981479)</td><td rowspan=1 colspan=1>ACL 9000</td><td rowspan=1 colspan=1>27.2</td><td rowspan=1 colspan=1>2.49</td></tr><tr><td rowspan=1 colspan=1>HemosILPT-Fibrinogen(K862301)</td><td rowspan=1 colspan=1>ACL Advance</td><td rowspan=1 colspan=1>22.6</td><td rowspan=1 colspan=1>1.24</td></tr><tr><td rowspan=1 colspan=1>HemosILPT-FibrinogenHS Plus(K060931)</td><td rowspan=1 colspan=1>ACL 300</td><td rowspan=1 colspan=1>41.3</td><td rowspan=1 colspan=1>1.56</td></tr><tr><td rowspan=3 colspan=1>Activated PartialThromboplastin(APTT)(Seconds)</td><td rowspan=1 colspan=1>HemosILAPTT-SP(K973306)</td><td rowspan=1 colspan=1>ACL 9000</td><td rowspan=1 colspan=1>47.9</td><td rowspan=1 colspan=1>1.69</td></tr><tr><td rowspan=1 colspan=1>HemosILSynthAFax(K955638)</td><td rowspan=1 colspan=1>ACL 6000</td><td rowspan=1 colspan=1>40.9</td><td rowspan=1 colspan=1>1.26</td></tr><tr><td rowspan=1 colspan=1>HemosILSynthASil(K060688)</td><td rowspan=1 colspan=1>ACL Advance</td><td rowspan=1 colspan=1>47.2</td><td rowspan=1 colspan=1>1.26</td></tr></table>

# 510(k) Summary (Cont.)

# Summary Performance Data (Cont.):

Precision   

<table><tr><td rowspan=1 colspan=5>HemosIL Routine Control Level 3</td></tr><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>Reagent</td><td rowspan=1 colspan=1>Instrument</td><td rowspan=1 colspan=1>Mean(n=80)</td><td rowspan=1 colspan=1>Within-Run%CV</td></tr><tr><td rowspan=3 colspan=1>ProthrombinTime (PT)(Seconds)</td><td rowspan=1 colspan=1>HemosILPT-FibrinogenRecombinant(K981479)</td><td rowspan=1 colspan=1>ACL 9000</td><td rowspan=1 colspan=1>37.0</td><td rowspan=1 colspan=1>2.65</td></tr><tr><td rowspan=1 colspan=1>HemosILPT-Fibrinogen(K862301)</td><td rowspan=1 colspan=1>ACL Advance</td><td rowspan=1 colspan=1>31.4</td><td rowspan=1 colspan=1>2.61</td></tr><tr><td rowspan=1 colspan=1>HemosILPT-FibrinogenHS Plus(K060931)</td><td rowspan=1 colspan=1>ACL 300</td><td rowspan=1 colspan=1>63.5</td><td rowspan=1 colspan=1>1.40</td></tr><tr><td rowspan=3 colspan=1>Activated PartialThromboplastin(APTT)(Seconds)</td><td rowspan=1 colspan=1>HemosILAPTT-SP(K973306)</td><td rowspan=1 colspan=1>ACL 9000</td><td rowspan=1 colspan=1>60.7</td><td rowspan=1 colspan=1>0.62</td></tr><tr><td rowspan=1 colspan=1>HemosILSynthAFax(K955638)</td><td rowspan=1 colspan=1>ACL 6000</td><td rowspan=1 colspan=1>55.4</td><td rowspan=1 colspan=1>1.98</td></tr><tr><td rowspan=1 colspan=1>HemosILSynthASil(K060688)</td><td rowspan=1 colspan=1>ACL Advance</td><td rowspan=1 colspan=1>56.3</td><td rowspan=1 colspan=1>1.14</td></tr></table>

Instrumentation Laboratory Co. C/o Carol Marble 113 Hartwell Avenue Lexington, Massachusetts 02421

# DEC 1 9 2008

Rc: k082859 Trade/Device Name: HemoslL Routine Control Level 1, 2, and 3 Regulation Number: 21 CFR 864.5425 Regulation Name: Multipurpose System for In Vitro Coagulation Studies Regulatory Class: Class II Product Code: GGN Dated: September 26, 2008 Received: September 29, 2008

Dear Ms. Marble:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class Ⅱ (Special Controls) or class Ⅲ (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820). This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed

Page 2 - Ms. Marble

predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desirc specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at 240-276-0450.Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, Interational and Consumer Assistance at its tol-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours, Cantli   
Actjug Division Director   
Division of Immunology and Hematology Devices   
Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and Radiological Health

Enclosure

# Indications for Use Statement

# 510(k) Number (if known):

![](images/a0d45093b7de9175ccffe9044a04bb73019a643835790ba0a637f74811cf3ae1.jpg)

Device Name: HemosIL Routine Control Levels 1, 2 and 3

# Indications for Use:

− HemosIL Routine Control Level 1 is for the quality control of coagulation assays in the normal range. The product is intended in the assessment of precision and accuracy for PT, APTT and Fibrinogen tests performed on coagulation systems. HemosIL Routinc Control Level 2 is for thc quality control of coagulation assays in the low abnormal range. The product is intended in the assessment of precision and accuracy for PT and APTT tests performed on coagulation systems.   
C HemosIL Routine Control Level 3 is for the quality control of coagulation assays in the high abnormal range. The product is intended in the assessment of precision and accuracy for PT and APTT tests performed on coagulation systems.

For in vitro diagnostic use.

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Unl Lartide   
visipy Sigon   
Office of In Vitro Diagnostic Devic   
Evaluation and Safety   
510(k) K082857